Group 1 - The Ministry of Finance and the State Taxation Administration announced the resumption of VAT on interest income from newly issued government bonds, local government bonds, and financial bonds starting from August 8 [1] - The Hong Kong High Court ruled that Zong Fuli cannot withdraw or transfer any assets from the bank account of Jianhao Venture Capital Limited until the litigation results are finalized [1] - The U.S. non-farm payrolls increased by only 73,000 in July, the lowest in nine months, significantly below the expected 110,000, indicating a rapid slowdown in the labor market [1] Group 2 - The central bank emphasized the implementation of a moderately loose monetary policy and enhancing the effectiveness of monetary policy measures [2] - The National Development and Reform Commission plans to accelerate the establishment of new policy financial tools to support private enterprises in major national projects [2] - The Supreme Court issued judicial interpretations on labor disputes, clarifying that agreements not to participate in social insurance are invalid [2] Group 3 - The Ministry of Finance reported six typical cases of local government hidden debt, with Xiamen, Chengdu, and Wuhan East Lake New Technology Development Zone adding hidden debts of 68.396 billion, 61.408 billion, and 10.385 billion respectively [3] Group 4 - The A-share market experienced a decline, with the Shanghai Composite Index falling by 0.37% to 3559.95 points, and the total trading volume for the day was 1.62 trillion [4] - The Hong Kong Hang Seng Index closed down 1.07% at 24507.81 points, marking four consecutive days of decline [5] Group 5 - The Hong Kong Stock Exchange published a consultation summary on optimizing IPO pricing and public market regulations, allowing a reduction in the minimum allocation ratio for IPO book-building from 50% to 40% [5] - The Shanghai Stock Exchange clarified that pre-application consultation is not a mandatory procedure for project acceptance [5] Group 6 - In the electric vehicle sector, July delivery figures showed significant growth for several companies, with Leap Motor surpassing 50,000 deliveries for the first time [9] - The Ministry of Industry and Information Technology issued a digital transformation implementation plan for the machinery industry, aiming for 50% of enterprises to reach a maturity level of two or above by 2027 [10] Group 7 - The State Administration of Foreign Exchange outlined key tasks for foreign exchange management, emphasizing the need for macro-prudential management of cross-border capital flows [21] - The onshore RMB closed at 7.2106 against the USD, down 176 basis points from the previous trading day [21]

Group 1 - Nobelpharma's melatonin product, Manlejing®, has been approved for sale in China, specifically for improving sleep difficulties in children aged 6-15 with neurodevelopmental disorders, marking it as the first melatonin formulation approved for this indication in the country [1][2] - Huate Dain has announced that its subsidiary, Dain Health, has signed an exclusive distribution agreement for Manlejing® in mainland China, with an initial term of 10 years [1][2] - The product was previously launched in Japan in 2020 and has shown significant results in reducing sleep latency in clinical trials [2] Group 2 - Other companies, such as Changchun High-tech and Eifang Pharmaceutical, have already established a presence in the market for treating sleep difficulties associated with neurodevelopmental disorders in children [3] - Huate Dain is a leading player in the children's pharmaceutical health sector in China, with its main revenue and profit sources coming from its subsidiary, Dain Pharmaceutical, which focuses on the development, production, and marketing of children's medications [3]

每经AI快讯，有投资者在投资者互动平台提问：近期二级市场行情火爆，贵公司股价却萎靡不振，坊 间传闻贵公司半年度业绩不佳，一些消息灵通的大户提前撤退，将筹码抛售给不明真相的散户。请问是 否属实？ 华特达因（000915.SZ）8月1日在投资者互动平台表示，公司2025年半年度报告定于2025年8月8日披 露，业绩情况请您以公司披露的《2025年半年度报告》为准。 （文章来源：每日经济新闻） ...

Core Viewpoint - Huate Dain (000915.SZ) has signed an exclusive distribution agreement with Nobelpharma Co., Ltd for melatonin granules (brand name: Manlejing®) in mainland China, marking a significant step in addressing the treatment gap for sleep difficulties in children with neurodevelopmental disorders [1] Group 1 - Huate Dain's subsidiary, Beijing Dain Kangjian Pharmaceutical Co., Ltd, will be the exclusive distributor for Manlejing® in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The product is set to be approved for market launch in China by July 2025, targeting children aged 6-15 with sleep difficulties [1] - This agreement allows Huate Dain to manage the import, marketing, and sales of the product, fulfilling a critical clinical need in the domestic market [1]

Group 1 - The company Huate Dain announced that its subsidiary Beijing Dain Kangjian has reached an agreement with Japan's Nobel Pharma Co., Ltd. for the exclusive general distribution of melatonin granules (Manlejing®) in mainland China [1] - Dain Kangjian will be the exclusive general distributor of this product in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The product is expected to be approved for sale in China by July 2025 and is the first melatonin formulation approved for treating sleep difficulties in children aged 6-15 with neurodevelopmental disorders in the country [1]

Core Viewpoint - The company Huate Dain (000915.SZ) has reached an agreement with Japan's Nobel Pharma Co., Ltd. for the exclusive distribution of melatonin granules (Manlejing®) in mainland China, marking a significant development in the pediatric sleep disorder treatment market [1] Company Summary - Huate Dain's subsidiary, Beijing Dain Kangjian, will serve as the exclusive distributor for the melatonin product in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The product is set to be approved for market launch in China by July 2025 [1] - Manlejing® is the first melatonin formulation approved in China for treating sleep difficulties in children aged 6-15 with neurodevelopmental disorders [1] - This product represents the first instance of a melatonin-based substance receiving marketing authorization as a pharmaceutical in China [1]

Core Viewpoint - The company Huate Dain (000915) has reached an exclusive distribution agreement for melatonin granules (Manlejing) with Japan's Nobel Pharma, marking a significant development in the pediatric sleep disorder treatment market in China [1] Group 1: Company Developments - Huate Dain's subsidiary, Beijing Dain Kangjian, will serve as the exclusive distributor for the melatonin product in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The product is set to be approved for market release in China by July 2025 [1] Group 2: Product Significance - Manlejing is the first melatonin formulation approved in China for treating sleep difficulties in children aged 6-15 with neurodevelopmental disorders [1] - This product represents the first instance of a melatonin-based substance receiving drug approval in China [1]

Group 1 - The company announced that its subsidiary, Beijing Dainkang Health Pharmaceutical Co., Ltd., has reached an agreement with Japan's Nobori Pharmaceutical Co., Ltd. for the exclusive general distribution of melatonin granules (brand name: Manlejing) in mainland China [1] - According to the agreement, Dainkang Health will become the exclusive distributor of Nobori's melatonin granules in mainland China, responsible for the product's import, marketing, and sales [1]

Group 1 - The core point of the article is that Huate Dain (000915.SZ) has reached an agreement with Japan's Noborin Pharmaceutical Co., Ltd. for exclusive distribution rights of melatonin granules (brand name: Manlejing®) in mainland China [1] - The agreement stipulates that Dain Kangjian will be the exclusive distributor for Noborin's melatonin granules in mainland China, responsible for the import, marketing, and sales of the product [1]

证券代码：000915 证券简称：华特达因 公告编号 2025-030 山东华特达因健康股份有限公司 关于子公司签署褪黑素颗粒（曼乐静®）总经销合同的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、合同签署概况 近日，山东华特达因健康股份有限公司（以下简称公司）的子公司北京达因 康健医药有限责任公司（以下简称达因康健）与日本诺贝仁制药株式会社 （Nobelpharma Co.,Ltd）（以下简称"诺贝仁"）就褪黑素颗粒（商品名：曼乐静 ®）在中国大陆地区的独家总经销事宜达成一致，并签署了《褪黑素颗粒总经销 协议》。根据协议约定，达因康健将成为诺贝仁旗下褪黑素颗粒产品（曼乐静®） 在中国大陆地区（不含港澳台）的独家总经销商，全面负责该产品的进口、市场 推广及销售。 1. 该产品 2025 年 7 月已在中国获批上市，商品名为"曼乐静®"； 三、合同主要内容 1. 授权范围：诺贝仁授予达因康健褪黑素颗粒产品在中国大陆地区（不含港 澳台）的独家经销权，包括产品的进口、市场推广及销售。 2. 合作期限：协议初始期限为 10 年，届满后经双方协商可续签。 3. ...